1. 42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas. (5th March 2018) Authors: Harb, W; Abramson, J; Lunning, M; Goy, A; Maddocks, K; Lebedinsky, C; Senderowicz, A; Trojer, P; Bradley, W D; Flinn, I Journal: Annals of oncology Issue: Volume 29(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. (9th February 2018) Authors: Jurczak, W; Zinzani, P L; Gaidano, G; Goy, A; Provencio, M; Nagy, Z; Robak, T; Maddocks, K; Buske, C; Ambarkhane, S; Winderlich, M; Dirnberger-Hertweck, M; Korolkiewicz, R; Blum, K A Journal: Annals of oncology Issue: Volume 29:Number 5(2018) Page Start: 1266 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗